YAVNE, Israel, Oct. 7, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company’s NexoBrid® will be featured in multiple oral and poster presentations at the 17th Congress of the International Society for Burn Injuries (ISBI) taking place October 12-16, 2014 in Sydney, Australia. The presentation abstracts will be available online at www.isbi.org.
NexoBrid will be presented at the ISBI conference to an audience of the world’s leading burn teams that include surgeons and other clinical specialists who treat patients with severe burns. NexoBrid is an easy-to-use, topically-applied, pharmaceutical product that removes dead or damaged tissue, known as eschar, in four hours without harming the surrounding healthy tissues. NexoBrid received marketing authorization from the European Medicines Agency and the Israeli Ministry of Health for the removal of eschar in adults with deep partial and full-thickness thermal burns, and has been commercially launched in Europe.
“We are delighted to have NexoBrid featured so prominently at this year’s ISBI, one of the world’s premier clinical meetings focused on the treatment and prevention of burns. The ISBI brings together the entire team of clinical professionals involved in caring for patients with severe burns including burn surgeons, anesthesiologists, critical care physicians, nurses, dietitians, occupational, physical therapists, and administrators, responsible for the implementation of burn care in normal and mass casualties conditions on national and international levels,” stated Gal Cohen, President and Chief Executive Officer of MediWound.
“The presentations at ISBI highlight experience gained in clinical studies, which demonstrate with statistical significance that NexoBrid successfully debrides burn wounds much earlier than the current standard-of-care, and significantly reduces the number and extent of surgical excision and autografting,” he added. “The ability to promptly and effectively remove the eschar without surgery, allows for the direct visual assessment of burn severity while significantly reducing surgical burden on patients as well as on health systems.”
“We are particularly pleased to see German physicians sharing their hands on experience with NexoBrid following our recent launch of NexoBrid in Germany. We are also very pleased that the role that NexoBrid could play in preparing for potential burn mass casualty disasters where surgical capacity might be limited and rapid severity assessment and intervention are imperative will be discussed during the Congress,” concluded Mr. Cohen.
The following abstracts regarding NexoBrid have been accepted for presentation by the ISBI organizing committee:
| Paper Title: | “Enzymatic debridement and negative pressure wound therapy combined use in a burned patient” |
| Date/Time: | October 13th from 10:30 a.m. – 12:00 p.m. |
| Location: | Level 4, Room 5 |
| Paper Title: | “Summary of pediatric clinical trial experience with NexoBrid” |
| Date/Time: | October 13th from 3:30 p.m. – 5:00 p.m. |
| Location: | Level 4, Room 3 |
| Paper Title: | “The role of an effective fast and specific enzymatic debriding agent (NexoBrid) in the care of mass burns in a disaster scenario” |
| Date/Time: | October 14th from 3:45 p.m. – 5:00 p.m. |
| Location: | Level 4, Room 3 |
| Paper Title: | “Summary of experience with NexoBrid enzymatic debridement of deeply burned hands” |
| Date/Time: | October 15th from 8:00 a.m. – 10:00 a.m. |
| Location: | Level 4, Room 4 |
| Paper Title: | “Long term scarring and quality of life in NexoBrid vs. SOC debrided burn patients: Results of a controlled trial” |
| Date/Time: | October 15th from 8:00 a.m. – 10:00 a.m. |
| Location: | Level 4, Room 4 |
| E-Poster Title: | “Burn debridement with NexoBrid: Results of a multinational, randomized controlled trial” |
About the ISBI
The International Society for Burn Injuries (ISBI) had its beginnings at the First International Congress on Research in Burns in Bethesda, Maryland in September 1960. Since the ISBI was founded, the total medical care of burn patients has improved considerably. This is not only because medical science has improved but also because there is also a better understanding of the need for a team of professionals of different specialties such as surgeons, anesthetists, bacteriologists, critical care physicians, nurses, dietitians, physiotherapists and others. Each and every one of these specialists plays a very important role. One of the main purposes and aims of the ISBI is to disseminate knowledge and to stimulate prevention in the field of burns.
About NexoBrid
NexoBrid is an easy-to-use, topically-applied pharmaceutical product that removes dead or damaged tissue, known as eschar, in four hours without harming the surrounding healthy tissues. NexoBrid was granted marketing authorization from the European Medicines Agency for the removal of eschar in adults with deep partial and full-thickness thermal burns, and was commercially launched in Europe. Representing a new paradigm in burn care management, NexoBrid demonstrated in clinical studies, with statistical significance, its ability to nonsurgically and rapidly remove the eschar earlier than other modalities, without harming viable tissues. The removal of eschar or “debridement” is a critical first step in the successful healing of severe burns and chronic and other hard-to-heal wounds. With the current standard-of-care (SOC), burn eschar is removed either with existing topical agents that have been found to be minimally effective or that take a significantly longer period of time to work, or by resorting to non-selective surgery, which is traumatic and may result in loss of blood and viable tissue.
About MediWound Ltd.
MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com.
Contacts:
Sharon Malka
CFO
MediWound
ir@mediwound.co.il
Anne Marie Fields
Senior Vice President
LHA
212-838-3777
afields@lhai.com
Help employers find you! Check out all the jobs and post your resume.
